Summary: A neurogenetics study revealed that APOE ε4, a genetic variant famously recognized as the primary risk factor for Alzheimer’s disease, also dictates the destructive spread of pathology in amyotrophic lateral sclerosis (ALS). The research establishes that ALS is not a uniform condition, but rather a disease of biologically distinct subtypes heavily influenced by a patient’s genetic profile.
By examining autopsy-confirmed cases, investigators proved that APOE ε4 carriers face a vastly higher probability of developing a severe, brain-wide subtype of ALS that extends far beyond motor neurons to trigger cognitive decline and dementia.
Key Facts
- The Protein Footprint of ALS: ALS is a progressive neurodegenerative disease that destroys motor neurons—the vital nerve cells governing movement, speech, swallowing, and respiration. Its primary pathological signature is the toxic accumulation of an abnormal protein called phosphorylated TDP-43 (pTDP-43) within the brain and spinal cord.
- The Pathological Subtypes: The spread of pTDP-43 varies drastically between individuals. In Type 1 ALS, the protein pathology remains strictly confined to motor-related regions. In Type 2 ALS, the pathology migrates aggressively into the frontal lobes, temporal lobes, and the hippocampus, heavily impairing cognition and behavior.
- The APOE ε4 Catalyst: Analyzing neuropathological data from 145 autopsy-confirmed sporadic ALS cases, researchers discovered that 65.5% of APOE ε4 carriers exhibited the widespread Type 2 pathology, compared to only 39.7% of non-carriers.
- An Independent Mechanism: Advanced machine learning and structural equation modeling demonstrated that APOE ε4 drives the spread of toxic TDP-43 through a unique biological pathway that is entirely independent of traditional Alzheimer’s-related changes, such as amyloid-β or tau accumulation.
- A Blueprint for Personalized Medicine: This discovery provides clinicians with a critical genetic window to anticipate early cognitive impairment, schedule precise psychological audits, tailor advanced communication infrastructure, and map out compassionate timing for choices like ventilatory support.
Source: Niigata University
A research team at the Brain Research Institute, Niigata University has found that APOE ε4, a genetic factor best known for increasing the risk of Alzheimer’s disease, may also influence how pathological changes spread in amyotrophic lateral sclerosis (ALS).
The findings were published online in Acta Neuropathologica.
ALS is a progressive neurodegenerative disease that affects motor neurons, the nerve cells that control movement, speech, swallowing, and breathing. In most patients with ALS, an abnormal form of a protein called phosphorylated TDP-43, or pTDP-43, accumulates inside neural cells in the brain and spinal cord. This protein pathology is considered one of the most important clues to understanding how ALS develops and progresses.
However, the spread of pTDP-43 pathology varies greatly from patient to patient. In some individuals, it remains largely restricted to motor-related regions. In others, it extends widely into areas such as the frontal and temporal lobes and the hippocampus, which are involved in cognition and behavior.
Patients with more widespread pathology are more likely to develop cognitive impairment or dementia. Until now, the factors that determine these differences in pathological spread have remained unclear.
The Niigata University team focused on APOE ε4, a genetic variant widely known as a risk factor for Alzheimer’s disease. Recent research has suggested that APOE ε4 may affect not only Alzheimer’s-related proteins such as amyloid-β and tau, but also the accumulation and spread of abnormal proteins in other neurodegenerative diseases. The researchers therefore asked whether APOE ε4 might also be associated with the distribution of TDP-43 pathology in ALS.
To investigate this, the team analyzed genetic and neuropathological data from 145 autopsy-confirmed sporadic ALS cases. They classified ALS cases into two pathological subtypes: type 1, in which TDP-43 pathology is mainly limited to motor-related regions; and type 2, in which pathology extends more broadly to the frontotemporal lobes, hippocampus, and other brain regions. They then examined the relationship between these pathological patterns and APOE ε4.
The results showed that patients carrying APOE ε4 were more likely to have widespread type 2 TDP-43 pathology. Specifically, 65.5% of APOE ε4 carriers had type 2 pathology, compared with 39.7% of non-carriers.
Importantly, further statistical analyses suggested that the effect of APOE ε4 on TDP-43 pathology was independent of Alzheimer’s disease–related pathology, including amyloid-β and tau accumulation.
Using structural equation modeling and machine learning approaches, the researchers also considered other factors such as age, disease duration, rare variants in ALS-related genes, and neuropathological findings.
“Our findings suggest that APOE ε4 may influence ALS pathology through mechanisms distinct from those involved in Alzheimer’s disease,” said Dr. Ishihara. “This provides a new perspective on why ALS pathology spreads differently among patients.”
The study highlights the importance of viewing ALS not as a single uniform disease, but as a condition with biologically distinct subtypes shaped by both pathology and genetic background.
In the future, information about APOE genotype may help clinicians better anticipate cognitive changes, plan the timing of cognitive assessments, discuss treatment choices such as ventilatory support, and prepare communication support tailored to each patient.
Although further studies are needed to confirm these findings and clarify the underlying mechanisms, this discovery offers a new clue toward personalized medicine in ALS and the development of treatments based on disease subtype.
Key Questions Answered:
A: Absolutely not. Carrying the APOE ε4 variant simply means you possess a genetic risk factor that influences how abnormal proteins accumulate and move if a neurodegenerative disease begins to manifest. Having the gene variant does not mean you will develop ALS. What this landmark study reveals is a shared vulnerability mechanism: if an individual already has ALS, carrying the APOE ε4 gene acts like an internal accelerator, pushing the existing disease to spread past basic motor areas into cognitive centers.
A: For a long time, science treated neurodegenerative diseases as completely isolated silos, assuming Alzheimer’s genes only messed with Alzheimer’s proteins. Niigata University completely shattered that assumption. By tracking the behavior of pTDP-43 (the core toxic protein in ALS), researchers proved that APOE ε4 has a multi-tasking destructive capacity. It doesn’t need amyloid-β or tau to cause damage; it possesses a distinct, independent mechanism that facilitates the rapid, broad migration of ALS pathology into the frontal and temporal lobes.
A: This is a monumental leap toward personalized medicine for ALS. Because the disease moves with terrifying speed, families and doctors are constantly forced to play catch-up. By testing a patient’s APOE genotype immediately upon diagnosis, clinicians can accurately predict whether they are highly vulnerable to the cognitive Type 2 subtype. This allows families to proactively plan specialized communication support, customize the perfect timing for cognitive evaluations, and make calm, clear decisions about long-term treatments like ventilatory support before a crisis hits.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this genetics and ALS research news
Author: Yuya Hatano
Source: Niigata University
Contact: Yuya Hatano – Niigata University
Image: The image is credited to Neuroscience News
Original Research: Open access.
“APOE ε4 influences the widespread TDP-43 pathological subtype in sporadic amyotrophic lateral sclerosis” by Yuya Hatano, Asa Nakahara, Mari Tada, Akiyoshi Kakita, Osamu Onodera & Tomohiko Ishihara. Acta Neuropathologica
DOI:10.1007/s00401-026-03029-y
Abstract
APOE ε4 influences the widespread TDP-43 pathological subtype in sporadic amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder, most sporadic cases exhibiting TAR DNA-binding protein 43 (TDP-43) pathology. The anatomical distribution of TDP-43 pathology varies among patients; however, factors contributing to this heterogeneity remain unclear.
Apolipoprotein E (APOE) ε4 is known to influence the spread of pathological protein in several neurodegenerative diseases, raising the possibility that it also modulates the pathological distribution of TDP-43 inclusions in ALS.
We investigated this hypothesis in a cohort of 145 autopsy-confirmed sporadic ALS cases. ALS-associated TDP-43 pathology was classified into two subtypes: type 1 – largely restricted to motor regions – and type 2 – characterized by widespread cortical involvement. APOE genotypes and rare variants in known ALS-associated genes were determined by exome sequencing.
Amyloid-β and tau pathologies were assessed neuropathologically using established staging systems. Structural equation modeling (SEM) was applied to disentangle direct and indirect relationships among APOE ε4, temporal clinical parameters, Alzheimer’s disease-related pathologies, and ALS TDP-43 subtype.
Furthermore, we also performed an unbiased evaluation using random forest model. APOE ε4 carriers showed a significantly higher proportion of type 2 pathology than non-carriers.
Bayesian SEM demonstrated that APOE ε4 was directly associated with the type 2, widespread TDP-43 subtype, independent of amyloid-β and tau pathology, while also reproducing the canonical cascade linking APOE ε4 to amyloid-β and tau. Rare variants in ALS-associated genes showed no clear effect on TDP-43 subtype.
These findings indicate that APOE ε4 modifies the anatomical distribution of TDP-43 pathology in sporadic ALS through mechanisms independent of classical Alzheimer’s disease pathology. Incorporation of APOE genotype into ALS stratification may be informative for biologically grounded subtype-specific therapeutic approaches.
